These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9786488)

  • 1. The in-vitro activities of co-amoxiclav and other oral antibiotics against Streptococcus pneumoniae isolates exhibiting intermediate susceptibility to penicillin.
    Washington JA; Felmingham D
    J Antimicrob Chemother; 1998 Sep; 42(3):405-6. PubMed ID: 9786488
    [No Abstract]   [Full Text] [Related]  

  • 2. Differences between the activity of penicillin, amoxycillin, and co-amoxyclav against 5,252 Streptococcus pneumoniae isolates tested in the Alexander Project 1992-1996.
    Butler DL; Gagnon RC; Miller LA; Poupard JA; Felmingham D; Grüneberg RN
    J Antimicrob Chemother; 1999 Jun; 43(6):777-82. PubMed ID: 10404316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin.
    Amores R; Alou L; Giménez MJ; Sevillano D; Gómez-Lus ML; Aguilar L; Prieto J
    Int J Antimicrob Agents; 2004 Jul; 24(1):79-82. PubMed ID: 15225866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the degree of penicillin susceptibility of Streptococcus pneumoniae affect the bactericidal activity of co-amoxiclav versus oral cephalosporins at physiological concentrations? An in vitro pharmacodynamic simulation.
    Prieto J; Giménez MJ; Balcabao IP; Gómez-Lus ML; Aguilar L
    J Chemother; 1999 Oct; 11(5):345-8. PubMed ID: 10632379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The postantibiotic effect of amoxicillin/clavulanic acid on Streptococcus pneumoniae strains of different serotypes and penicillin sensitivity].
    García Y; Gómez MJ; Ramos MC; Gómez-Lus ML; Prieto J
    Rev Esp Quimioter; 1998 Jun; 11(2):157-60. PubMed ID: 9795302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
    Pottumarthy S; Fritsche TR; Sader HS; Stilwell MG; Jones RN
    Int J Antimicrob Agents; 2005 Apr; 25(4):282-9. PubMed ID: 15784306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro activity of a combination of two oral beta-lactams (cefpodoxime and amoxycillin) against Streptococcus pneumoniae isolates with reduced susceptibilities to penicillin.
    Johnson DM; Jones RN
    J Antimicrob Chemother; 1998 Oct; 42(4):555-7. PubMed ID: 9818764
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro activity and pharmacodynamics of oral beta-lactam antibiotics against Streptococcus pneumoniae from southeast Missouri.
    Kays MB; Wood KK; Miles DO
    Pharmacotherapy; 1999 Nov; 19(11):1308-14. PubMed ID: 10555936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation.
    Sevillano D; Calvo A; Giménez MJ; Alou L; Aguilar L; Valero E; Carcas A; Prieto J
    J Antimicrob Chemother; 2004 Dec; 54(6):1148-51. PubMed ID: 15489246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Neuhauser MM; Prause JL; Danziger LH; Pendland SL
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3613-5. PubMed ID: 11709352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers.
    Alou L; Aguilar L; Sevillano D; Giménez MJ; Laguna B; Echeverría O; Carcas A; Lubomirov R; Casal J; Prieto J
    J Antimicrob Chemother; 2005 May; 55(5):742-7. PubMed ID: 15761068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.
    Hoogkamp-Korstanje JA; Dirks-Go SI; Kabel P; Manson WL; Stobberingh EE; Vreede RW; Davies BI
    J Antimicrob Chemother; 1997 Mar; 39(3):411-4. PubMed ID: 9096192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What pharmacodynamic elements affect Augmentin in man?].
    Jehl F
    Presse Med; 1998 Sep; 27 Suppl 4():20-1. PubMed ID: 9798482
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G; Berry V
    Antimicrob Agents Chemother; 1999 Jan; 43(1):35-40. PubMed ID: 9869562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Choice of antibiotics in lower respiratory infections: what does pharmacodynamics bring? Clinical application of pharmacodynamic data].
    Goldstein F
    Presse Med; 1998 Sep; 27 Suppl 4():22-3. PubMed ID: 9798483
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative in-vitro activity of penicillin alone and combined with gentamicin against clinical isolates of Streptococcus pneumoniae with decreased susceptibility to penicillin.
    Anadiotis L; Maskell JP; Sefton AM
    Int J Antimicrob Agents; 2002 Mar; 19(3):173-81. PubMed ID: 11932138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of Streptococcus pneumoniae resistant to penicillin in the USA and in-vitro susceptibility to selected oral antibiotics.
    Mason EO; Lamberth L; Lichenstein R; Kaplan SL
    J Antimicrob Chemother; 1995 Dec; 36(6):1043-8. PubMed ID: 8821604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Amoxicillin/clavulanic acid (875/125 mg). New pharmacodynamic aspects].
    Lode H
    Dtsch Med Wochenschr; 1999 Dec; 124(48):1459-61. PubMed ID: 10615328
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative activity of ampicillin, amoxycillin, amoxycillin/clavulanate and cefotaxime against 189 penicillin-susceptible and -resistant pneumococci.
    Pankuch GA; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1995 Jun; 35(6):883-8. PubMed ID: 7559200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.